Meeting Report
27–30 June 2017 Manila, Philippines
Амстердам, Нидерланды, 23 июля 2018 г.
Отчет
Programme Brief
Accessed: 21.08.2019
Краткое содержание лекций семинара. На семинаре обсуждались ключевые проблемы в регионе, связанные с заболеваемостью ВИЧ, туберкулезом и гепатитом у людей, употре...бляющих наркотики инъекционно, а также тема «ВИЧ, подростки и молодежь».
more
Child Survival Working Group
Accessed: 02.11.2019
UNICEF’s Global HIV Response 2018 – 2021
Accessed: 02.11.2019
How the Greek reception system is failing to protect the most vulnerable people seeking asylum.
Greece and its EU partners are failing pregnant women, unaccompanied children, victims of torture or sexual violence and other vulnerable people who seek protection in Europe. These people are being put ...at risk by flawed processes and chronic understaffing in EU ‘hotspot’ camps on the Greek islands. They do not receive adequate support from the authorities that are legally responsible for protecting them and are being abandoned in overcrowded camps in squalid conditions. Many people live in unheated tents and do not have sufficient access to washing facilities and toilets, and winter is only making their situation worse
more
The uneven distribution of HIV risks and burdens across populations is a well-substantiated fact, though seldom publicly acknowledged. Gay men and other men who have sex with men, people who inject drugs, sex workers, and transgender women are 24, 24, 13.5, and 49 times more likely to acquire HIV, ...respectively, than other reproductive aged adults (15 years old and older). Globally, new infections among these key populations account for 45% of all new HIV infections. This figure is likely to be an underestimate, given the intense stigma associated with disclosing and reporting acquisition risks for HIV among gay men, people who use drugs, sex workers, and transgender people. In addition, HIV epidemics in the majority of low- and middle-income countries (90 of 120) have concentrated epidemics among key populations. In countries with more broadly generalized epidemics, risks are still not evenly distributed and key populations still shoulder disease burden that is markedly disproportionate.
more
HIV Treatment and Care
Fact Sheet
July 2018
The National Guidelines for HIV-1 Viral Load Laboratory Testing support plans to scale up viral load (VL) testing to reach the 90-90-90 targets in India. This phased scale-up includes the setup of 70 additional VL testing laboratories nationally. These guidelines include laboratory design considerat...ions, a summary of VL technologies, and specimen collection and handling as well as transportation and storage guidance. Quality control and quality assurance requirements are described as well as laboratory safety issues. The guidelines also describe the VL laboratory network to be developed with supply chain management issues and commodities described. Annexes include laboratory registers and reporting forms.
more
A new respiratory infectious disease, COVID-19, caused by a new coronavirus called SARS-CoV-2, emerged in early December 2019. Since then, the virus has spread to India and 106 other countries in Asia, Europe, North America, Africa, and Oceania. On March 11, the World Health Organization (WHO) decl...ared the outbreak a pandemic, which has since rapidly evolved. As an economic hub with substantial global connectivity and movement of people and goods, India is directly impacted by the COVID-19 pandemic. Although it is too early to gauge the full spectrum of the outbreak’s social and economic impacts, COVID-19 has already caused lockdowns in China, Korea, and in many countries in Europe, and in some states of India, suspension of schools and universities, disruption of food systems and other supply chains, as well as a slowdown in trade between India and rest of the world.
more
Issue #6| 23 March– 05 April 2020
This document is part three in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. Part two focused on the ingredients in a vaccine and the three clinical trial phases.
This document outlines the... next part of the vaccine journey: the steps from completing the clinical trial phases through to distribution.
more
The case for evidence- based communication of science